Status:

TERMINATED

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Lead Sponsor:

AEterna Zentaris

Collaborating Sponsors:

Dana-Farber Cancer Institute

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a...

Detailed Description

A pre-planned interim analysis is expected to take place in Q1 of 2013.

Eligibility Criteria

Inclusion

  • Patient was previously diagnosed with multiple myeloma based on standard diagnostic criteria.
  • Patients must have relapsed (progressed \> 60 days) after their last dose of bortezomib-based therapy. In addition, patients may be relapsed or refractory to other non-bortezomib-based therapies.
  • Patient has received at least 1 but not more than 4 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen.
  • Patients must have adequate organ and marrow function.

Exclusion

  • Patients must not be refractory to any bortezomib-containing regimen.
  • History of allergic reactions or intolerance attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine), bortezomib or dexamethasone or any of their components.
  • Prior treatment with perifosine or an investigational proteasome inhibitor.
  • Chemotherapy or other therapy experimental or proven that is or may be active against myeloma within two weeks (14 days) prior to Cycle 1 Day 1.

Key Trial Info

Start Date :

December 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

135 Patients enrolled

Trial Details

Trial ID

NCT01002248

Start Date

December 1 2009

End Date

March 1 2013

Last Update

February 9 2018

Active Locations (86)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 22 (86 locations)

1

La Verne, California, United States, 91750

2

San Francisco, California, United States, 94143

3

San Pablo, California, United States, 94806

4

Aurora, Colorado, United States, 80012